A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines

Allergan0 sites33 target enrollmentMay 2013

ConditionsChronic Migraine, Headaches

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Chronic Migraine, Headaches
Sponsor: Allergan
Enrollment: 33
Primary Endpoint: Change From Baseline in the Number of Headache Days
Status: Completed
Last Updated: 10 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

This study will evaluate the effectiveness and benefit of treatment with onabotulinumtoxinA in Chronic Migraine patients who have received a minimum of 7 treatment cycles.

Registry

clinicaltrials.gov

Start Date

May 2013

End Date

May 2014

Last Updated

10 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Allergan

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•15 or more headache days over a 30 day period
•A minimum of 7 treatment cycles with onabotulinumtoxinA

Exclusion Criteria

•Any treatment cycle dose of onabotulinumtoxinA greater than 200 units

Outcomes

Primary Outcomes

Change From Baseline in the Number of Headache Days

Time Frame: Treatment Cycle 7 (approximately 1.5 years)

The mean number of headache days was counted as the number of headache days occurring during the 30 day period ending with treatment cycle 7. Each treatment cycle was administered approximately every 12 weeks.